Patterns of Urinary Bladder Cancer in Darfur, Suda

Status Completed

Clinical Trial Summary

Background: Bladder cancer (BC) exhibits extreme heterogeneity regarding clinical outcome, etiology, histology, and geographic distribution. Recent clinical observations point to alterations in the BC pattern in the Sudan, possibly as a result of lifestyle changes brought on by the enormous migration from rural to urban locations. This study aimed to identify the pattern of bladder cancer in Darfur. Patients and Methods: A cross sectional, hospital-based study, it was conducted inNyala specialized hospital, during the period from (2020 to 2022), included one hundred and five patients with bladder mass matching the inclusion criteria were studied over the diversity of demographic data , clinical finding, pathological type and possible risk factors .

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06156787
Study type	Observational
Source	National Center for Gastroentestinal and Liver Disease
Contact
Status	Completed
Phase
Start date	November 1, 2020
Completion date	April 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00872495` - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Withdrawn	`NCT05335707` - Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Completed	`NCT03998579` - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer	N/A
Not yet recruiting	`NCT04525781` - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed	`NCT02897765` - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer	Phase 1
Recruiting	`NCT05822934` - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer	Phase 3
Completed	`NCT02722538` - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer	Phase 1
Completed	`NCT02437539` - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography	Phase 1
Completed	`NCT02139371` - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography	Phase 0
Completed	`NCT03433924` - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting	`NCT03132922` - MAGE-A4ᶜ¹º³²T for Multi-Tumor	Phase 1
Completed	`NCT05946369` - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Completed	`NCT00462488` - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ	Phase 2
Recruiting	`NCT05621837` - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting	`NCT05644041` - Intravesical Gemcitabine in Patients With NMIBC	Phase 2
Completed	`NCT04635566` - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute	N/A
Recruiting	`NCT04861584` - Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects	Phase 2
Completed	`NCT01836978` - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy	N/A
Terminated	`NCT01374789` - PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer	Phase 2
Recruiting	`NCT03844256` - A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study	Phase 1/Phase 2